

## DICHIARAZIONE DI ACCETTAZIONE DELLA CANDIDATURA ALLA CARICA DI AMMINISTRATORE DI GENENTA SCIENCE S.P.A.

Il sottoscritto Francesco Galimi, nato a Torino il 4 giugno 1967, residente a 12930 Via Esperia, Del Mar CA 92014, USA, codice fiscale GLMFNC67H04L219B,

### premessò che

- è stato designato quale candidato alla carica di Amministratore di Genenta Science S.p.A., con sede legale in Milano, Via dell'Annunciata 31, codice fiscale e numero di iscrizione al Registro delle Imprese di Milano Monza Brianza Lodi 08738490963 (la "Società") ai fini della nomina del Consiglio di Amministrazione della Società prevista al punto 2 dell'ordine del giorno della Assemblea Ordinaria e Straordinaria degli Azionisti, convocata in sede ordinaria e straordinaria, esclusivamente in teleconferenza, in prima convocazione per il giorno 29 giugno 2026 alle ore 17:00 e, occorrendo, in seconda convocazione per il giorno 30 giugno 2026 alle ore 17:30;

- è a conoscenza dei requisiti previsti dalla vigente normativa e dalle disposizioni dello statuto sociale della Società per l'assunzione della carica di Amministratore;


### tutto ciò premesso, dichiara sotto la propria responsabilità:

- di accettare la candidatura e l'eventuale nomina alla carica di Amministratore della Società;
- l'inesistenza di cause di ineleggibilità e di incompatibilità con la carica di Amministratore ai sensi di legge e dello statuto sociale;
- di possedere tutti i requisiti prescritti dalla normativa vigente per ricoprire la carica di Amministratore;
- l'assenza di cause di ineleggibilità previste dal Codice Civile e di interdizioni dall'ufficio di amministratore adottate nei propri confronti in uno Stato membro dell'Unione Europea;
- di autorizzare fin d'ora la pubblicazione del *curriculum vitae*, atto a fornire esauriente informativa sull'esperienza professionale e caratteristiche personali.

Si allegano: *curriculum vitae*; documento di identità.

4 giugno 2026

Firma:



# FRANCESCO GALIMI, MD PhD

## Chief Medical Officer - Board Member

[fgalimi@gmail.com](mailto:fgalimi@gmail.com) | [linkedin.com/in/fgalimi](https://www.linkedin.com/in/fgalimi)

### SUMMARY

- Experienced physician-scientist and physician-executive with a 30+ year career in medicine, both in academia and in the bio-pharmaceutical industry.
- Track record of leadership of cross-functional organizations, from preclinical research to registrational activities and commercial strategy.
- Thirty years of experience in hematology and oncology R&D.
- Board certified in Medical Oncology in the EU.
- Extensive experience in medical teaching (25+ years).

### RECENT EXPERIENCE OVERVIEW

**Board Member** Since 2025

**Acting CMO and Head of Development**

**Genenta, Inc. (now Saentra Forge, Inc.)** Milan, Italy

Only Italian-based company currently listed on the U.S. technology market.

**Chief Medical Officer** Since 2025

**OverT Bio, Inc.** New York City, NY

Clinical-stage cell therapy company.

**Chief Medical Officer** Since 2025

**Antharis Therapeutics, Inc.** San Diego, CA

Clinical-stage ADC company.

**Chief Medical Officer** Since 2025

**Cervero Therapeutics, Inc.** San Diego, CA

Clinical-stage small molecule company.

**Senior Vice President and Chief Medical Officer** 2019-2024

**Adicet Bio, Inc.** Redwood City, CA

Member of the Executive Leadership Team. Accountable for the Company's portfolio of oncology and autoimmune cell therapy programs. Played a critical role in investor-facing activities, resulting in 2 successful public offerings totaling \$200+ million.

**Global Program General Manager** 2014-2019

**Amgen, Inc.** Thousand Oaks, CA

Accountable for the cross-functional strategy and execution of a portfolio of drug development programs, from pre-IND to late-stage development.

**Head of Clinical Development** 2013-2014

**Onyx Pharmaceuticals, Inc.** South San Francisco, CA

Accountable for leadership and management of the Clinical Dev group.

Prior industry experience includes roles of increasing responsibility at **Amgen** and **Novartis** in research, early development, and late development.

### EDUCATION AND TRAINING

- M.D., Cum Laude, University of Torino, Italy 1991
- Ph.D. in Human Oncology, University of Torino, Italy 1995
- Fellow in Medical Oncology, Dept. of Biomedical Sciences, University of Torino 1995-1999
- EU Board of Medical Oncology 1999
- Postdoctoral Fellow, Salk Institute, La Jolla, CA 1998-2003

### Core Competencies

- Member of Executive Leadership Teams and Boards of Directors in private and public biotech companies
- Corporate Director experience
- Medical and scientific lead in interactions of private and public biotech companies with investors and pharma partners
- Broad and deep hands-on experience in bio-pharmaceutical R&D, across different therapeutic modalities (small molecules, antibodies, peptibodies, antibody-drug conjugates, oncolytic viral vectors, immunotherapy and cell therapy programs) in all phases of development
- Leadership of complex development plans from early clinical to commercial and payor/access strategy
- Deep and broad expertise in assessing preclinical data, clinical trial designs, regulatory pathways, and market landscape to evaluate the likelihood of clinical, regulatory, and commercial success
- US, EU, UK, Eastern Europe, Japan and China regulatory interactions in 25+ IND/CTA and NDA/BLA filings
- Design, execution, and analysis of global phase I-II-III clinical trials in malignant and non-malignant hematology, oncology and rheumatology therapeutics, including large phase III registrational studies
- Implementation of companion diagnostic strategies for patient identification and pharmacodynamic biomarkers
- Superior leadership, interpersonal, and communication skills

### Languages

- English, Italian, French

### Nationality

- Italian/American dual citizen

## Table of Contents

<b>PERSONAL INFORMATION.....</b>	<b>3</b>
Contact Info.....	3
Nationality.....	3
Marital Status.....	3
<b>EDUCATION.....</b>	<b>3</b>
Medical Studies.....	3
Postdoctoral Training.....	3
Languages.....	3
<b>INDUSTRY EXPERIENCE.....</b>	<b>4</b>
Regulatory Experience.....	6
Patents.....	6
<b>ACADEMIC APPOINTMENTS.....</b>	<b>7</b>
Teaching and Mentoring Activities.....	7
<b>RESEARCH EXPERIENCE.....</b>	<b>7</b>
Fellowships and Awards.....	8
Societies.....	8
Editorial Activities.....	8
<b>PROFESSIONAL PRACTICE AND CERTIFICATIONS.....</b>	<b>8</b>
<b>PUBLICATIONS.....</b>	<b>9</b>
Selected Invited Presentations.....	9
Full Papers and Reviews.....	9
Cellular and Molecular Biology of the Hepatocyte Growth Factor (1993 - 2001).....	9
Lentiviral-mediated Gene Transfer Models of Human Disease (2002 - 2014).....	10
Translational Medicine and Early Clinical Development (2012 - present).....	12

**PERSONAL INFORMATION**

**Contact Info** 12930 Via Esperia  
Del Mar, CA 92014, USA  
[fgalimi@gmail.com](mailto:fgalimi@gmail.com)  
+1 (805) 669-7278

**Nationality** Italian/American dual citizen

**Marital Status** Married, two children

**EDUCATION****Medical Studies**

- 1991 M.D., *Cum Laude*  
University of Torino Medical School, Torino, Italy
- 1995 Ph.D. in Human Oncology  
University of Torino Medical School, Torino, Italy
- 1999 Specialty Certification in Medical Oncology (EU Board of Medical Oncology), University of Torino Medical School, Torino, Italy

**Postdoctoral Training**

- 1995 – 1999 Fellow in Medical Oncology, Dept. of Biomedical Sciences,  
University of Torino Medical School, Torino, Italy
- 1998 – 2003 Postdoctoral Fellow, Dr. Inder Verma's Laboratory,  
The Salk Institute for Biological Studies, La Jolla, California

**Languages**

- Native Italian speaker
- 1982 French, Diplôme de l'Alliance Française
- 1986 English, Cambridge Certificate of Proficiency in English,  
University of Cambridge (UK)

**INDUSTRY EXPERIENCE**

- Since 2025 **Board Member, Acting Chief Medical Officer and Head of Development**  
**Genenta, Inc. (now Saentra Forge, Inc.)** **Milan, Italy**
- Serves on the Board of Directors of Saentra Forge (Nasdaq: SAEN) (formerly Genenta, Inc. - Nasdaq: GNTA), a holding company focused on acquiring businesses in national-security sectors such as defense, aerospace, cybersecurity, and biotechnology.
  - Member of the Compensation, Nomination and Governance Committee.
- Since 2025 **Chief Medical Officer**  
**OverT Bio, Inc.** **New York City, NY**
- Strategic guidance and overseeing of the clinical transition of the Company's cell therapy portfolio, IND submissions, build-up of the clinical organization.
- Since 2025 **Chief Medical Officer**  
**Antharis Therapeutics, Inc.** **San Diego, CA**
- Strategic guidance and overseeing of the clinical transition for the Company's antibody-drug conjugate portfolio, IND submissions, build-up of the clinical organization.
- Since 2025 **Chief Medical Officer**  
**Cervero Therapeutics, Inc.** **San Diego, CA**
- Strategic guidance and overseeing of the clinical transition for the Company's small molecule portfolio, IND submissions, build-up of the clinical organization.
- Since 2025 **Principal**  
**FG Consulting, Inc.** **Del Mar, CA**
- Clinical development consultancy services.
- 2019 – 2024 **Senior Vice President and Chief Medical Officer**  
**Adicet Bio, Inc.** **Redwood City, CA**
- Member of the Executive Leadership Team, reporting directly to the Chief Executive Officer.
  - Built and led the Company's clinical organization from the ground up including Clinical Development, Medical Affairs, Translational Medicine, Regulatory, Biostatistics, Clinical

Operations, Data Management, Program Management and Program Leadership.

- Played a critical role in investor-facing activities, resulting in 2 successful rounds of public offering totaling \$200+ million.

2015 – 2019 **Global Program General Manager**

**Amgen, Inc.**

**Thousand Oaks, CA**

- Reporting directly into CEO Staff, managed the cross-functional strategy and execution of a portfolio of immuno-oncology drug development programs, from pre-IND to late-stage.
- Accountable for both development strategy and global launch planning and execution.
- Team lead for small molecule and immunotherapy programs, including AMG 176, AMG 387 (MCL1 inhibitors), oprozomib (proteasome inhibitor), AMG 420, AMG 701, AMG 424 (bispecific T-cell engagers).

2014 – 2015 **Head of Clinical Development**

**Onyx Pharmaceuticals, Inc.**

**South San Francisco, CA**

- Accountable for leadership and management of the Clinical Development group at Onyx (50+ staff members including MDs, PhDs, PharmDs, medical writers and administrative staff).
- Main focus was on carfilzomib and oprozomib (proteasome inhibitors).

2011 – 2014 **Executive Director, Oncology Translational Medicine**

**Novartis, Inc.**

**San Diego, CA and Cambridge, MA**

- Key activities: responsible for the early development strategy and execution of a portfolio of small molecule, antibody-drug conjugate, and immunotherapy programs.
- Responsible for providing clinical input and organizational alignment to research teams at Novartis sites located on the West Coast of the US.
- Clinical lead for multiple small molecule and antibody-drug conjugate programs in phase I-II.

2007 – 2011 **Clinical Research Medical Director**

**Amgen, Inc.**

**Thousand Oaks, CA**

- Key activities: design, conduct, and analysis of multiple global clinical trials across major indications in oncology therapeutics.
- Served as Medical Director for all the pro-apoptotic antibody clinical studies in the company's pipeline centered on the TRAIL agonists conatumumab and dulanermin. Served as Medical representative on regulatory interactions and filing activities.
- Served as Medical Director on phase III registrational studies for small molecules (motesanib) and oncolytic viral vectors (talimogene laherparepvec).
- Implemented innovative workflows for clinical data review in the context of medical/safety monitoring and database validation activities.

- Managed complex global cross-functional teams through all stages of translational and clinical development.

2006 – 2007 **Early Development Team Leader**

**Amgen, Inc.**

**Thousand Oaks, CA**

- Key activities: lead early development teams, from clinical candidate identification to first-in-human studies.
- Main focus was on thrombopoietin agonists (romiplostim).

2004 – 2006 **Principal Scientist**

**Amgen, Inc.**

**Thousand Oaks, CA**

- Key activities: lead a team of 6 through the inception and execution of a number of discovery research programs in oncology and hematology.
- Identified clinical candidates which moved to first-in-human.
- Supported the licensing department in evaluating external opportunities.

**Regulatory Experience**

From 2006 to 2026, served as Clinical Lead, Program Lead, Department Head, or Chief Medical Officer on 30+ clinical-stage programs from pre-IND to phase 3 (INDs, CTAs, NDAs, BLAs).

Details available upon request.

**Patents**

US 6,030,949	Macrophage stimulating protein for the treatment of pathologies of the nervous system.
US 2004/ 0235169 A1	Inducible expression of transfected genes.
US 7,981,425	Thrombopoietic compounds.
ITMI971248	Proteina stimolante i macrofagi come agente protettivo della tossicità renale indotta da farmaci.
EP0880971 B1	Macrophage stimulating protein for the treatment of pathologies of the nervous system.
WO2023102264A1	Treatment of B-cell malignancies.

## ACADEMIC APPOINTMENTS

- 2006 – present **Associate Professor of Histology**  
University of Sassari Medical School, Sassari, Italy
- 1997 – 2005 **Assistant Professor of Histology**  
University of Sassari Medical School, Sassari, Italy

## Teaching and Mentoring Activities

- 1999 – present Mentoring of M.S. and Ph.D. students interested in establishing a career in the pharma/biotech sector
- 2000 – 2018 Graduate Advisor, Ph.D. program in Molecular Biology and Biochemistry, University of Sassari
- 1999 – 2018 Course Director, Gene Therapy and Transfer, University of Sassari Medical School
- 1999 – 2018 Course Director, Histology and Embryology, University of Sassari Medical School
- 1997 – 1999 Lecturer, Histology and Embryology, University of Sassari Medical School

## RESEARCH EXPERIENCE

- 2004 – 2006 **Senior Scientist (2004) and Principal Scientist (2005-2006)**  
**Amgen, Inc.**  
**Thousand Oaks, California**
- Key activities: lead a team of 6 through the inception and execution of a portfolio of discovery research programs in oncology and hematology.
  - Identified clinical candidates which moved to first-in-human.
- 1998 – 2003 **Postdoctoral Fellow, Dr. Inder Verma's Laboratory**  
**The Salk Institute for Biological Studies**  
**La Jolla, California**
- Research focused on lentiviral-mediated gene transfer models of disease (see *Publications*).
- 1991 – 1999 **PhD student and Fellow in Medical Oncology**  
**Department of Biomedical Sciences**  
**University of Torino Medical School, Torino, Italy**
- Research focused on the biology of Hepatocyte Growth Factor (see *Publications*).

### **Fellowships and Awards**

- 2000 Forbeck Foundation Scholar Award
- 1999 – 2002 José Carreras International Leukemia Foundation Scholarship
- 1996 – 1997 FIRC Fellowship in Molecular Oncology (Italian Foundation for Cancer Research)
- 1991 – 1995 Ph.D. Fellowship (Italian Ministry of Scientific Research)

### **Societies**

- American Society of Gene Therapy (ASGT)
- American Society of Hematology (ASH)
- American Society of Clinical Oncology (ASCO)
- European Society of Medical Oncology (ESMO)
- American Association for Cancer Research (AACR)

### **Editorial Activities**

- Ad hoc* reviewer: Blood  
 Molecular Therapy  
 Human Gene Therapy  
 Journal of Gene Therapy

## **PROFESSIONAL PRACTICE AND CERTIFICATIONS**

- 1999 – present EU Medical Oncology Board
- 1995 – 1999 Fellow in Medical Oncology, Institute for Cancer Research and Treatment, Candiolo (Italy), and University of Torino Medical School
- 1994 – 1995 Medical Lieutenant, Italian Military Health Service. Served as Head of the Health Services in the Guardia di Finanza Academy, Mondovì, Italy
- 1992 – 1997 Consultant Physician, Blood Bank, San Giovanni Battista General Hospital, Torino, Italy
- 1992 – present General Practitioner (License no. 16132 - 27/01/1992, Ordine dei Medici della Provincia di Torino)
- 1991 EU Medical Licensing Exam, University of Torino Medical School

## PUBLICATIONS

### **Selected Invited Presentations**

EMBO Practical Course, Lentiviral Vectors for Gene Therapy, Turin 2000, *“Ex vivo gene transfer into Hematopoietic Stem Cells”*

ASGT 4th Annual Meeting, Seattle 2001, *“Gene Therapy of Fanconi Anemia by Lentiviral Vectors”*

Fanconi Anemia Symposium, Philadelphia 2002, *“Gene Therapy of Fanconi Anemia by Lentiviral Vectors”*

ASGT 8th Annual Meeting, St.Louis 2005, *“Regulation of Transgene Expression: Vector Designs and Applications”*

Immuno-oncology Frontiers, Miami 2018, *“Bispecific T-cell Engagers in Hematological Malignancies”*

4<sup>th</sup> Annual Immunotherapy in Myeloma Scientific Workshop, San Francisco 2018, *“Bispecific T-cell Engagers in Multiple Myeloma”*

4<sup>th</sup> Annual CAR-T Congress, Boston 2019, *“Bispecific Molecules in Hematological Malignancies”*

5<sup>th</sup> Annual Immunotherapy in Myeloma Scientific Workshop, Denver 2019, *“BCMA Bispecific Constructs in Multiple Myeloma”*

9<sup>th</sup> Whistler Global Summit on Hematological Malignancies, Whistler 2022, *“ADI-001: First-in-class Allogeneic Gamma Delta CD20 CAR T Cells in Non-Hodgkin’s Lymphoma”*

3<sup>rd</sup> Gamma Delta T Therapies Summit, Boston 2022, *“Bringing a First-in-Class Allogeneic CAR-Engineered Gamma Delta T Cell Therapy to the Clinic”*

5<sup>th</sup> Gamma Delta T Therapies Summit, Boston 2024, *“Gamma Delta-based Cell Therapy in Cancer and Autoimmune Diseases”*

### **Full Papers and Reviews**

#### *Cellular and Molecular Biology of the Hepatocyte Growth Factor (1993 - 2001)*

1. **Galimi, F.**, Brizzi, M.F., Comoglio, P.M. The hepatocyte growth factor and its receptor. Stem Cells. 1993;11 Suppl 2:22-30.
2. Giordano, S., Zhen, Z., Medico, E., Gaudino, G., **Galimi, F.**, Comoglio, P.M. Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET proto-oncogene. Proc Natl Acad Sci U S A. 1993;90:649-653.
3. Boccaccio, C., Gaudino, G., Gambarotta, G., **Galimi, F.**, Comoglio, P.M. Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. J Biol Chem. 1994;269:12846-12851.

4. **Galimi, F.**, Bagnara, G.P., Bonsi, L., Cottone, E., Follenzi, A., Simeone, A., Comoglio, P.M. Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors. *J Cell Biol.* 1994;127:1743-1754.
5. Negro, F., Papotti, M., Pacchioni, D., **Galimi, F.**, Bonino, F., Bussolati, G. Detection of human androgen receptor mRNA in hepatocellular carcinoma by in situ hybridisation. *Liver.* 1994;14:213-219.
6. **Galimi, F.**, Comoglio, P.M. Control of invasive cell growth by the Met family oncogenes. In: Mihich, E., Hausman, D., eds. *Cancer Genes: Functional Aspects.* New York: Plenum Publishing Corporation; 1995.
7. Naldini, L., Vigna, E., Bardelli, A., Follenzi, A., **Galimi, F.**, Comoglio, P.M. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. *J Biol Chem.* 1995;270:603-611.
8. Grano, M., **Galimi, F.**, Zambonin, G., Colucci, S., Cottone, E., Zallone, A.Z., Comoglio, P.M. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. *Proc Natl Acad Sci U S A.* 1996;93:7644-7648.
9. Graziani, A., **Galimi, F.**, Medico, E., Cottone, E., Gramaglia, D., Boccaccio, C., Comoglio, P.M. The HIV-1 nef protein interferes with phosphatidylinositol 3-kinase activation. *J Biol Chem.* 1996;271:6590-6593.
10. **Galimi, F.**, Cottone, E., Vigna, E., Arena, N., Boccaccio, C., Giordano, S., Naldini, L., Comoglio, P.M. Hepatocyte growth factor is a regulator of monocyte-macrophage function. *J Immunol.* 2001;166:1241-1247.

*Lentiviral-mediated Gene Transfer Models of Human Disease (2002 - 2014)*

11. **Galimi, F.**, Noll, M., Kanazawa, Y., Lax, T., Chen, C., Grompe, M., Verma, I.M. Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors. *Blood.* 2002;100:2732-2736.
12. **Galimi, F.**, Verma, I.M. Opportunities for the use of lentiviral vectors in human gene therapy. *Curr Top Microbiol Immunol.* 2002;261:245-254.
13. Beausejour, C.M., Krtolica, A., **Galimi, F.**, Narita, M., Lowe, S.W., Yaswen, P., Campisi, J. Reversal of human cellular senescence: roles of the p53 and p16 pathways. *EMBO J.* 2003;22:4212-4222.
14. Herzig, S., Hedrick, S., Morantte, I., Koo, S.H., **Galimi, F.**, Montminy, M. CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma. *Nature.* 2003;426:190-193.
15. Pastore, C., Picchio, G.R., **Galimi, F.**, Fish, R., Hartley, O., Offord, R.E., Mosier, D.E. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. *Antimicrob Agents Chemother.* 2003;47:509-517.
16. Tiscornia, G., Tergaonkar, V., **Galimi, F.**, Verma, I.M. CRE recombinase-inducible RNA interference mediated by lentiviral vectors. *Proc Natl Acad Sci U S A.* 2004;101:7347-7351.

17. **Galimi, F.**, Saez, E., Gall, J., Hoong, N., Cho, G., Evans, R.M., Verma, I.M. Development of ecdysone-regulated lentiviral vectors. *Mol Ther.* 2005;11:142-148.
18. **Galimi, F.**, Summers, R.G., van Praag, H., Verma, I.M., Gage, F.H. A role for bone marrow-derived cells in the vasculature of non injured CNS. *Blood.* 2005;105:2400-2402.
19. Cantaluppi, V., Biancone, L., Romanazzi, G.M., Figliolini, F., Beltramo, S., Ninniri, M.S., **Galimi, F.**, Romagnoli, R., Franchello, A., Salizzoni, M., Perin, P.C., Ricordi, C., Segoloni, G.P., Camussi, G. Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation. *Am J Transplant.* 2006;6:2601-2611.
20. Horky, L.L., **Galimi, F.**, Gage, F.H., Horner, P.J. Fate of endogenous stem/progenitor cells following spinal cord injury. *J Comp Neurol.* 2006;498:525-538.
21. Solinas, G., Naugler, W., **Galimi, F.**, Lee, M.S., Karin, M. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. *Proc Natl Acad Sci U S A.* 2006;103:16454-16459.
22. Sternsdorf, T., Phan, V.T., Maunakea, M.L., Ocampo, C.B., Sohal, J., Silletto, A., **Galimi, F.**, Le Beau, M.M., Evans, R.M., Kogan, S.C. Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia. *Cancer Cell.* 2006;9:81-94.
23. Garcia-Rudaz, C., Luna, F., Tapia, V., Kerr, B., Colgin, L., **Galimi, F.**, Dissen, G.A., Rawlings, N.D., Ojeda, S.R. Fxna, a novel gene differentially expressed in the rat ovary at the time of folliculogenesis, is required for normal ovarian histogenesis. *Development.* 2007;134:945-957.
24. Maioli, M., Asara, Y., Pintus, A., Ninniri, S., Bettuzzi, S., Scaltriti, M., **Galimi, F.**, Ventura, C. Creating prodynorphin-expressing stem cells alerted for a high-throughput of cardiogenic commitment. *Regen Med.* 2007;2:193-202.
25. Heger, S., Mastronardi, C., Dissen, G.A., Lomniczi, A., Cabrera, R., Roth, C.L., Jung, H., **Galimi, F.**, Sippell, W., Ojeda, S.R. Enhanced at puberty 1 (EAP1) is a new transcriptional regulator of the female neuroendocrine reproductive axis. *J Clin Invest.* 2007;117:2145-2154.
26. Cantaluppi, V., Biancone, L., Romanazzi, G.M., Figliolini, F., Beltramo, S., **Galimi, F.**, Camboni, M.G., Deriu, E., Conaldi, P., Bottelli, A., Orlandi, V., Herrera, M.B., Pacitti, A., Segoloni, G.P., Camussi, G. Macrophage Stimulating Protein May Promote Tubular Regeneration after Acute Injury. *J Am Soc Nephrol.* 2008;19:1904-1918.
27. Dissen, G.A., Lomniczi, A., Neff, T.L., Hobbs, T.R., Kohama, S.G., Kroenke, C.D., **Galimi, F.**, Ojeda, S.R. In vivo manipulation of gene expression in non-human primates using lentiviral vectors as delivery vehicles. *Methods.* 2009;49:70-77.
28. Begemann, S., **Galimi, F.**, Karlseder, J. Moderate expression of TRF2 in the hematopoietic system increases development of large cell blastic T-cell lymphomas. *Aging.* 2009;1:122-130.
29. Colombino, M., Avallone, A., Izzo, F., Tatangelo, F., Budroni, M., Cossu, A., **Galimi, F.**, Comella, P., Botti, G., Sini, M.C., Palmieri, G. Molecular analysis of Fanconi anemia (FA) and mismatch repair (MMR) genes in patients with colorectal carcinoma. *Oncol Rep.* 2011; 25:899-904.

30. Dissen, G.A., McBride, J., Lomniczia, A., Matagnea, V., Dorfmana, M., Neffa, T.L., **Galimi, F.**, Ojeda, S.R. Using Lentiviral Vectors as Delivery Vehicles for Gene Therapy. In: Morozov, A., ed. Controlled Genetic Manipulations. Neuromethods, 2012, vol 65, pp 69-96. Humana Press, Totowa, NJ.
31. Cantaluppi, V., Biancone, L., Figliolini, F., Beltramo, S., Medica, D. Deregibusa, M.C., **Galimi, F.**, Romagnoli, R., Salizzoni, M., Tetta, C., Segoloni, G.P., Camussi, G. Microvesicles derived from endothelial progenitor cells enhance neoangiogenesis of transplanted human pancreatic islets. Cell Tranpl. 2012; 21:1305-20.
32. Lee, H.S., Ghetti, A., Pinto-Duarte, A., Wang, X., Dziejczapolski, G., **Galimi, F.**, Huitron-Resendiz, S., Pina-Crespo, J., Amanda J. Roberts, A.J., Verma, I.M., Sejnowski, T.J., Heinemann, S.F. Astrocytes contribute to gamma oscillations and recognition memory. Proc Natl Acad Sci U S A. 2014; 111:E3343-52.
33. Secchi, C., Carta, M., Crescio, C., Spano, A., Arras, M., Caocci, G., **Galimi, F.**, La Nasa, G., Pippia, P., Turrini, F., Pantaleo, A. T cell tyrosine phosphorylation response to transient redox stress. Cell Signal. 2015; 27:777-88.

*Translational Medicine and Early Clinical Development (2012 - present)*

34. Scagliotti, G.V., Vynnychenko, I., Park, K., Ichinose, Y., Kubota, K., Blackhall, F., Pirker, R., Galiulin, R., Ciuleanu, T., Sydorenko, O., Dediu, M., Papai-Szekely, Z., Martinez Banaclocha, N., McCoy, S., Yao, B., Hei, Y., **Galimi, F.**, Spigel, D.R., on behalf of the MONET1 Study Group. An International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1. J Clin Oncol. 2012; 30:2829-36.
35. Kindler, H.L., Richards, D.A., Garbo, L.E., Garon, E.B., Stephenson, J.J., Rocha-Lima, C.M., Safran, H., Chan, D., Kocs, D.M., **Galimi, F.**, McGreivy, J., Bray, S.L., Hei, Y., Feigal, E.G., Loh, E., Fuchs, C.S. A Randomized, Placebo-Controlled Phase 2 Study of Ganitumab (AMG 479) or Conatumumab (AMG 655) in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer. Ann Oncol. 2012; 23:2834-42.
36. Paz-Ares, A., Bálint, B., de Boer, R.H., van Meerbeeck, J.P., Wierzbicki, R., De Souza, P., **Galimi, F.**, Haddad, V., Sabin, T., Hei, Y., Pan, Y., Cottrell, S., Hsu, C.P., Ramlau, R. A Randomized Phase 2 Study of Paclitaxel and Carboplatin With or Without Conatumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Thor Oncol. 2013; 8:329-37.
37. Cohn, A.L., Taberner, J., Maurel, J., Nowara, E., Sastre, J., Chuah, B.Y.S., Kopp, M.V., Sakaeva, D.D., Mitchell, E.P., Dubey, S., Suzuki, S., Hei, Y., **Galimi, F.**, McCaffery, I., Pan, Y., Loberg, R., Cottrell, S., Choo, S.P. A Randomized, Placebo-Controlled Phase 2 Study of Ganitumab or Conatumumab in Combination With FOLFIRI for Second-Line Treatment of Mutant KRAS Metastatic Colorectal Cancer. Ann Oncol. 2013; 24:1777-85.
38. Fuchs, C., Fakih, M., Schwartzberg, L., Cohn, A., Yee, L., Dreisbach, L., Kozloff, M.F., Hei, Y., **Galimi, F.**, Pan, Y., Haddad, V., Hsu C.P., Sabin A., Saltz, L. TRAIL Agonist Conatumumab Plus

Modified FOLFOX6 and Bevacizumab for the First-line Treatment of Patients with Metastatic Colorectal Cancer: A Phase 1b/2 Clinical Trial. *Cancer*. 2013; 119:4290-8.

39. Tabernero, J., Chawla, S.P., Kindler, H., Reckamp, K., Chiorean, E.G., Azad, N.S., Lockhart, A.C., Hsu, C.P., Baker, N.F., **Galimi, F.**, Beltran, P., Baselga, J. Anti-cancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. *Targeted Oncology*. 2015; 10:65-76.
40. Caocci, G., Greco, M., Delogu, G., Secchi, C., Perra, A., Ghiani, S., Orru, F., Vacca, A., **Galimi, F.**, La Nasa, G. Ruxolitinib therapy and telomere length in myelofibrosis. *Blood Cancer J*. 2016; 6:e479.
41. Caocci, G., Greco, M., Delogu, G., Secchi, C., Martino, B., Labate, C., Abruzzese, E., Trawinska, M.M., Galimberti, S., Orru, F., Fozza, C., Gambacorti Passerini, C., **Galimi, F.**, La Nasa, G. Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients. *J Hematol Oncol*. 2016; 9:63.
42. Secchi, C., Orecchioni, M., Carta, M., **Galimi, F.**, Turrini, F., Pantaleo, A. Signaling Response to Transient Redox Stress in Human Isolated T Cells: Molecular Sensor Role of Syk Kinase and Functional Involvement of IL2 Receptor and L-Selectin. *Sensors (Basel)*. 2020; 20:466.
43. Svensson, M.N.D., Zoccheddu, M., Yang, S., Nygaard, G., Secchi, C., Doody, K.M., Slowikowski, K., Mizoguchi, F., Humby, F., Hands, R., Santelli, E., Sacchetti, C., Wakabayashi, K., Wu, D.J., Barback, C., Ai, R., Wang, W., Sims, G.P., Mydel, P., Kasama, T., Boyle, D.L., **Galimi, F.**, Vera, D., Tremblay, M.L., Raychaudhuri, S., Brenner, M.B., Firestein, G.S., Pitzalis, C., Ekwall, A.K.H., Stanford, S.M., Bottini, N.. Synoviocyte-targeted therapy synergizes with TNF inhibition in reversing arthritis. *Sci Adv*. 2020; 6:eaba4353.
44. Giordo, R., Nasrallah, G.K., Posadino, A.M., **Galimi, F.**, Capobianco, G., Eid, A.H., Pintus, G. Resveratrol-elicited PKC inhibition counteracts NOX-mediated endothelial to mesenchymal transition in human retinal endothelial cells exposed to high glucose. *Antioxidants*. 2021; 10: 224.

[LinkedIn Profile:](#)



[List of Publications \(ORCID\):](#)

